Yahoo Finance 
PCAS: 1st Half 2021 earnings report
Ecully, September 9, 2021
1st HALF 2021 EARNINGS REPORT
PCAS (Euronext Paris: PCA), a specialist in the development and production of complex molecules for life sciences and innovative technologies, announces the publication of its consolidated earnings for the first half of 2021.
| 30 June 2020 | 30 June 2021 | |||||
Net sales | 105.1 | 106.3 | |||||
EBITDA (*) | 7.2 | 8.0 | |||||
EBITDA margin | 6.9% | 7.5% | |||||
Current operating income (*) | -3.0 | -2.6 | |||||
Other operating income and expenses | -0.2 | -0.4 | |||||
Operating income | -3.2 | -3.0 | |||||
Financial result | -1.5 | -0.9 | |||||
Taxes | -1.1 | -1.3 | |||||
Net result | -5.8 | -5.2 | |||||
(*) of which research tax credit (CIR): 2.2 M€ in 2019 and 2.1 M€ in 2020 | |||||||
Results
The PCAS Group generated consolidated net sales of €106.3 million as of June 30, 2021, representing an increase of 1.1% compared to the same period in the previous financial year (+3.1% at a constant exchange rate).
EBITDA amounted to €8.0 million (€9.9 million at constant exchange rate) at June 30, 2021 versus €7.2 million at June 30, 2020.
Current operating income amounted to -€2.6 million (-€0.7 million at constant exchange rate) as of June 30, 2021, compared to -€3.0 million at June 30, 2020.
Net income amounted to -€5.2 million in the first half of 2021 versus -€5.8 million at June 30, 2020.
Outlook
As mentioned in our previous press releases since end-March 2020, the global coronavirus health crisis is changing by the day, with persistent uncertainty surrounding its duration, extent and impacts on corporate production lines as well as consumption in general.
The potential impacts in the medium term remain difficult to anticipate. This crisis still calls for cautious measures. Due to the exceptional circumstances, the Group has suspended its financial targets and strategic business objectives until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE:
Q3 2021 net sales, on November 4, 2021.
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With about 10% of net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for major market-leading global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in cutting-edge segments. PCAS generated net sales of €194.1 million in 2020 and employs nearly 1,100 people in six countries.
To find out more about PCAS: www.pcas.com
PCAS | NewCap |
|
|
Tel.: +33 1 69 79 60 00 | Tel.: +33 1 44 71 98 53 |
Attachment
